Top Markets
Coin of the day
Palvella Therapeutics, Inc. Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLA
Rank in Stocks #6151
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company... Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Share Price
$153.93
Market Cap
$2.21B
Change (1 day)
-0.26%
Change (1 year)
172.68%
Country
US
Trade Palvella Therapeutics, Inc. (PVLA)

Category

Stock split history for Palvella Therapeutics, Inc. (PVLA)
Palvella Therapeutics, Inc. stock (symbol: PVLA) underwent a total of 0 stock splits.
The most recent stock split occurred on Aug 27, 2026.
One PVLA share bought prior to Aug 27, 2026 would equal to 0 PVLA shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH